Company / Free Cash Flow
Corbus Pharmaceuticals Holdings, Inc. Free Cash Flow History
FY2015-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$48.2M
FY2022
5-year range
-$100.2M / -$28.5M
FY2018-FY2022
Trend
+51.8%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow returned to growth in FY2022 after 4 years of decline, reaching -$48M.
Based on SEC 10-K filings.
-$48M in FY2022.
Remained stable around -$48M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2022, free cash flow increased 51.8% year-over-year.
- Peak free cash flow was recorded in FY2015.
- Lowest free cash flow in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -12.48 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | -$48.2M | +51.8% |
| FY2021 | -$100.2M | -106.7% |
| FY2020 | -$48.5M | -49.7% |
| FY2019 | -$32.4M | -13.6% |
| FY2018 | -$28.5M | -501.5% |
| FY2017 | -$4.7M | +0.0% |
| FY2016 | -$4.7M | -95.4% |
| FY2015 | -$2.4M | - |
As of FY2022 · SEC 10-K · Updated Jun 24, 2026